Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02170064
Recruitment Status : Completed
First Posted : June 23, 2014
Results First Posted : September 1, 2014
Last Update Posted : September 20, 2017
Sponsor:
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
The purpose of this study is to characterize the pharmacokinetics of Eslicarbazepine acetate in children and adolescents with epilepsy.

Condition or disease Intervention/treatment Phase
Epilepsy Drug: BIA 2-093 (Eslicarbazepine acetate) Phase 2

Detailed Description:

This clinical study was planned to be performed as an open-label, single-centre, multiple-dose study, in 30 paediatric epileptic patients distributed by 3 age groups of 10 patients each: 2-6 years [Group 1], 7-11 years [Group 2], and 12-17 years [Group 3].

The study was constituted by a 4-week baseline phase, followed by 3 consecutive 4-week treatment periods with Eslicarbazepine acetate in which patients received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day (weeks 1-4), 15 mg/kg/day (weeks 5-8) and 30 mg/kg/day or 1800 mg/day, whichever less (weeks 9-12). At the end of each 4-week treatment period, patients were hospitalised and serial blood samples for drug assays were obtained over a dosing interval.

After the last treatment period or in the event of premature discontinuation, the dose had to be down-titrated during a 2-week period. After the last treatment period patient could continue receiving Eslicarbazepine acetate ("compassionate use") if both parent(s)/guardian(s) /patient and his/her physician agreed this was in the best patient's interest. A follow-up visit occurred approximately 4 weeks after the last hospitalisation or early discontinuation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy
Study Start Date : June 2005
Actual Primary Completion Date : April 2006
Actual Study Completion Date : April 2006


Arm Intervention/treatment
Experimental: Group 1 (2-6 yrs)

At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate ("compassionate use") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.

For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit.

Drug: BIA 2-093 (Eslicarbazepine acetate)
Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route

Experimental: Group 2 (7-11 years)

At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate ("compassionate use") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.

For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).

Drug: BIA 2-093 (Eslicarbazepine acetate)
Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route

Experimental: Group 3 (12-17 years)

At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate ("compassionate use") if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.

For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored).

Drug: BIA 2-093 (Eslicarbazepine acetate)
Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route




Primary Outcome Measures :
  1. Maximum Observed Plasma Drug Concentration (Cmax) Post-dose [ Time Frame: pre-dose, and ½, 1½, 3, 4½, 6 and 12 hours post-dose ]
  2. Time of Occurrence of Cmax (Tmax). [ Time Frame: pre-dose, and ½, 1½, 3, 4½, 6 and 12 hours post-dose ]

Secondary Outcome Measures :
  1. Percentage Change in Seizure Frequency During Each 4-week Treatment Period Compared to the Baseline Phase [ Time Frame: Baseline, end of 5 mg/kg/day treatment period (4 weeks), 15 mg/kg/day treatment period (4 weeks) and 30 mg/kg/day treatment period (4 weeks). ]

    The efficacy variables were the percentage change in seizure frequency during each 4-week treatment period compared to the baseline phase.

    Seizures were recorded in the patient's diary during the baseline phase and during the following 4-week treatment periods.

    Seizure frequency for each patient was standardised to a frequency per 28 days period (i.e., mean daily frequency multiplied by 28). Changes in seizure frequency were analysed for each age group separately.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

The following inclusion criteria were applied in selecting patients for participation in the trial.

Patient was eligible for entry into the baseline phase if he/she fulfilled the following criteria at Visit 1:

  • Written informed consent given by the parent(s)/guardian(s), and by the patient when appropriate.
  • Male or female patient aged between 2 and 17 years.
  • Body weight within the 10th and 90th percentiles, by age and sex.
  • A documented diagnosis of partial-onset seizures (simple or complex seizures with or without secondary generalisation), classified according to the International Classification of Epileptic Seizures.
  • Currently treated with 1 to 3 AEDs (any except OXC or CBZ), in a stable dosage regimen during at least 1 month prior to screening.
  • Good general health (apart from epilepsy) based on medical history and physical examination.
  • In case of a female patient, she was premenarchal, surgically sterile or presented a urine pregnancy test consistent with a non-gravid state and practiced an effective non-hormonal contraception method.

At Visit 2, patient was eligible for entry into the Eslicarbazepine acetate treatment phase if he/she fulfilled the following criteria:

  • At least 4 partial-onset seizures during the last 4 weeks of the baseline phase.
  • Brain CT scan or MRI that excluded rapidly progressive neurological diseases.
  • ECG without clinically significant abnormalities.
  • Good general health (apart from epilepsy) based on medical history, physical examination and laboratory tests at screening.
  • Diaries satisfactorily completed by the patient or his/her caregiver during the baseline phase.
  • Satisfactory compliance with the study requirements during the baseline phase.
  • In case of a female patient of childbearing potential, she presented a urine pregnancy test consistent with a non-gravid state and practiced an effective non-hormonal contraception method.

Exclusion Criteria:

Patient was not allowed for entry into the screening phase if he/she fulfilled the following criteria at Visit 1:

  • Primarily generalised epilepsy.
  • Clinically relevant medical condition, other than epilepsy.
  • History of status epilepticus in the last 3 months.
  • History of suicide attempt.
  • History of alcohol or drug abuse.
  • History of hypersensitivity or intolerance to OXC or CBZ.
  • Use of any investigational drug or participated in any clinical trial within the previous 2 months.
  • Patient and/or his/her caregiver(s) unlikely to co-operate with the requirements of the study.
  • If female, she was sexually active and of child-bearing potential and she did not use reliable contraception.
  • Patients with non-epileptic attacks (syncopes, pseudoseizures).
  • Previous poor compliance with anti-epileptic therapy.
  • Need for rescue benzodiazepines more frequently than twice per week on average.
  • Previous use of Eslicarbazepine acetate or participation in a clinical study with Eslicarbazepine acetate.
  • Any other condition or circumstance that, in the opinion of the investigator, might compromise the patient's ability to comply with the clinical trial protocol (CTP).

At Visit 2, patient was not eligible for entry into the Eslicarbazepine acetate treatment phase if he/she fulfilled the following criteria:

  • Inadequate compliance to concomitant AEDs during the baseline phase.
  • Clinically relevant clinical laboratory test abnormalities at screening.
  • Occurrence of any other condition or circumstance that, in the opinion of the investigator, might compromise the patient's ability to comply with the CTP.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02170064


Locations
Layout table for location information
Romania
Clinica de Neurologie Pediatrica, Spitalul "Alexandru Obregia"
Bucharest, Romania, 041914
Sponsors and Collaborators
Bial - Portela C S.A.

Layout table for additonal information
Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT02170064    
Other Study ID Numbers: BIA-2093-202
First Posted: June 23, 2014    Key Record Dates
Results First Posted: September 1, 2014
Last Update Posted: September 20, 2017
Last Verified: August 2017
Keywords provided by Bial - Portela C S.A.:
Epilepsy
BIA 2-093
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Eslicarbazepine acetate
Anticonvulsants
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action